A Phase IB Study of MEK162 plus Paclitaxel in Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Full Title

A Phase 1b Dose-Escalation Study of MEK162 in Combination with Weekly Paclitaxel in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer


Paclitaxel is a standard chemotherapy drug used to treat ovarian cancer. However, in many patients, the cancer persists or returns. The purpose of this study is to find the highest dose of an investigational drug called MEK162 that can be given in combination with paclitaxel in women with ovarian, fallopian tube, or primary peritoneal cancer that has returned despite therapy that included a platinum-containing drug.

MEK162 works by inhibiting a protein called MEK1/2, which can fuel cancer cell growth. It is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have ovarian, fallopian tube, or primary peritoneal cancer that returned despite one or more prior regimens of platinum-containing chemotherapy.
  • Patients must have recovered from the serious side effects of prior treatment before entering the study.
  • Patients must be able to be ambulatory for more than half of their normal waking hours.
  • This study is open to patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Rachel Grisham at 646-888-4653.